Literature DB >> 9160888

The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.

T Takahashi1, M Shibuya.   

Abstract

KDR/Flk-1 tyrosine kinase, one of the two receptors for Vascular Endothelial Growth Factor (VEGF) has been shown to generate the major part of mitotic signals in endothelial cells, although the mechanisms are poorly understood. Here we examined the processing and signal transduction of KDR/Flk-1. Both in endothelial cells and in NIH3T3 cells expressing KDR/Flk-1, an immature form of KDR/Flk-1 with a molecular mass of about 150 kDa was glycosylated to create a 200 kDa intermediate, and after further glycosylation a mature 230 kDa was expressed on the cell surface. Only this 230 kDa form was rapidly and transiently phosphorylated on tyrosine residues in the presence of VEGF. As a major substrate of KDR/Flk-1, PLC-gamma was found to be rapidly tyrosine-phosphorylated and associated with KDR/Flk-1 both in endothelial cells and NIH3T3 cells. Interestingly, however, a prompt activation of MAP kinase and subsequent strong mitotic signaling were generated only in the endothelial cell background. Activation of MAP kinase in NIH3T3 cells overexpressing KDR/Flk-1 showed a slower response as maximum levels were only attained after 20 min compared to 5 min in sinusoidal endothelial cells. These results suggest that the KDR/Flk-1 utilizes cell type-specific signal transduction pathway(s) for MAP kinase activation and the mitotic response in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160888     DOI: 10.1038/sj.onc.1201047

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  78 in total

1.  Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch.

Authors:  M Félétou; J Staczek; J Duhault
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.

Authors:  J Kankanala; A M Latham; A P Johnson; S Homer-Vanniasinkam; C W G Fishwick; S Ponnambalam
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Vascular endothelial growth factor stimulates dephosphorylation of the catenins p120 and p100 in endothelial cells.

Authors:  E Y Wong; L Morgan; C Smales; P Lang; S E Gubby; J M Staddon
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

4.  The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.

Authors:  Antonietta Rosella Farina; Antonella Tacconelli; Lucia Cappabianca; Gesilia Cea; Sonia Panella; Antonella Chioda; Alessandra Romanelli; Carlo Pedone; Alberto Gulino; Andrew Reay Mackay
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

5.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.

Authors:  Meng Tong; Brandon Lloyd; Ping Pei; Susan R Mallery
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

6.  A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters.

Authors:  David M Roberts; Amanda L Anderson; Michihiro Hidaka; Raymond L Swetenburg; Cam Patterson; William L Stanford; Victoria L Bautch
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

7.  Vascular endothelial growth factor acts through novel, pregnancy-enhanced receptor signalling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells.

Authors:  Mary A Grummer; Jeremy A Sullivan; Ronald R Magness; Ian M Bird
Journal:  Biochem J       Date:  2009-01-15       Impact factor: 3.857

8.  Caspase8 rs1035142 G>T polymorphism was associated with an increased risk of esophageal cancer in a Chinese population.

Authors:  Jun Yin; Weifeng Tang; Aizhong Shao; Liming Wang; Xu Wang; Guowen Ding; Chao Liu; Yijang Chen; Suocheng Chen; Haiyong Gu
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

9.  New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab.

Authors:  Argirios Moustakas; Teri N Kreisl
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

10.  Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice.

Authors:  Malgorzata Milkiewicz; Christopher W Pugh; Stuart Egginton
Journal:  J Physiol       Date:  2004-08-19       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.